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Abstract
We aimed to characterize circulating microparticles in association with arterial stiffness, inflammation and endothelial
dysfunction in aldosterone-salt-induced hypertension in rats and to investigate the preventive effects of red wine
polyphenols. Uninephrectomized male Sprague-Dawley rats were treated with aldosterone-salt (1 mg.h21), with or without
administration of either red wine polyphenols, ProvinolsTM (20 mg.kg21.day21), or spironolactone (30 mg.kg21.day21) for 4
weeks. Microparticles, arterial stiffness, nitric oxide (NO) spin trapping, and mesenteric arterial function were measured.
Aldosterone-salt rats showed increased microparticle levels, including those originating from platelets, endothelium and
erythrocytes. Hypertension resulted in enhanced aortic stiffness accompanied by increased circulating and aortic NO levels
and an upregulation of aortic inducible NO-synthase, NFkB, superoxide anions and nitrotyrosine. Flow-induced dilatation
was reduced in mesenteric arteries. These effects were prevented by spironolactone. ProvinolsTM did not reduce arterial
stiffness or systolic hypertension but had effects similar to those of spironolactone on endothelial function assessed by flow-
mediated vasodilatation, microparticle generation, aortic NO levels and oxidative stress and apoptosis in the vessel wall.
Neither the contractile response nor endothelium-dependent relaxation in mesenteric arteries differed between groups. The
in vivo effects of ProvinolsTM were not mediated by mineralocorticoid receptors or changes in shear stress. In conclusion,
vascular remodelling and endothelial dysfunction in aldosterone-salt-mediated hypertension are associated with increased
circulating microparticles. Polyphenols prevent the enhanced release of microparticles, macrovascular inflammation and
oxidative stress, and microvascular endothelial dysfunction independently of blood pressure, shear stress and
mineralocorticoid receptor activation in a model of hyperaldosteronism.
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Introduction
Mineralocorticoid administration to uninephrectomized rats
drinking a concentrated salt solution is a well known model of
experimental hypertension and the degree of hypertension is
dependent on the duration of the aldosterone-salt regimen. An
increase in systolic arterial pressure (SAP) was observed after
administration of aldosterone and salt for 4 weeks in rats. Key
aspects of this model are the maintenance of the deleterious effect
of salt in presence of relatively high levels of aldosterone and the
presence of proteinuria and increased oxidative stress compared
with uninephrectomized rats on a normal salt diet [1]. Further-
more, an increase in arterial stiffness, assessed by the incremental
elastic modulus (Einc), was also observed within this time-frame
[2]. The mineralocorticoid receptor antagonists, eplerenone and
spironolactone, have been shown to prevent these arterial changes,
together with the associated cardiac fibrosis, independently of left
ventricular hypertrophy, via blood pressure reduction [3]. In
hypertensive patients, eplerenone treatment has been recently
shown to reduce stiffness in resistance arteries [4]. For endothelial
function, a number of studies have shown that chronic treatment
with aldosterone resulted in impaired acetylcholine-induced
relaxation of the aorta in both normotensive and hypertensive
rats resulting from inflammatory and oxidative processes [5].
Microparticles may also play a key role in endothelial
dysfunction and vascular oxidative stress. Indeed, microparticles
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are small membrane vesicles that are shed from cells in response to
activation and apoptosis in various disease states [6]. Because of
their presence in the bloodstream, circulating microparticles may
be considered to play a major role in interactions with circulating
cells or the components of the vessel wall. Recently, it has been
reported that hypertensive patients displayed both elevated levels
of circulating endothelial microparticles and increased arterial
stiffness assessed by brachial–ankle pulse wave velocity [7].
Furthermore, microparticles promote endothelial dysfunction in
metabolic syndrome patients with moderate hypertension [8]. To
the best of our knowledge, the circulating levels of microparticles
according to their cellular origin have never been characterized in
aldosterone-salt hypertension.
Red wine polyphenols, including ProvinolsTM, possess beneficial
properties for preventing cardiovascular disorders by their
influence on nitric oxide (NO) balance and prevention of oxidative
stress. These compounds can decrease blood pressure in normo-
tensive rats [9], an effect which involves the NO pathway because
polyphenols are able to induce ex vivo endothelium-dependent
relaxation as a result of enhanced NO synthesis via endothelial
NO synthase (eNOS) [10]. We [11,12] and other groups [13] have
provided evidence that ProvinolsTM reduce blood pressure in
several experimental models of hypertension, and can correct
cardiovascular remodelling and vascular dysfunction. Further-
more, our recent manuscript shows that delphinidin in Provi-
nolsTM activated the NO pathway (Src, ERK 1/2, eNOS,
caveolin-1), leading to NO production in endothelial cells via
activation of the a isoform of the oestrogen receptor [14]. An
increase in NOS activity, the prevention of oxidative stress, and a
reduction in the inflammatory process may explain the effects of
ProvinolsTM.
The uninephrectomized aldosterone-salt rat model is widely
used for measuring the cardiovascular effects of aldosterone. We
chose to use the classical reference group of uninephrectomized
rats as controls and not uninephrectomized animals receiving a
high salt diet, since the renin level is markedly decreased in these
latter animals [15]. We consider also the model of aldosterone
infusion and salt without uninephrectomy as an unsuitable control,
because the specific involvement of mineralocorticoid receptor has
not been definitively established. Indeed, the effects of mineral-
ocorticoid receptor antagonism have never been described in this
model [16].
In the present study, our aim was first to characterize circulating
microparticles according to their cellular origin and to study their
role in association with arterial stiffness, vascular inflammation
and endothelial dysfunction in aldosterone-salt-induced hyperten-
sion from uninephrectomized rats. Secondly, we investigated the
cardio-protective effects of ProvinolsTM on the consequences of
aldosterone-salt-induced hypertension on the above parameters,
i.e. microparticles, large artery stiffness, inflammation and
oxidative stress, and flow-induced dilatation in uninephrectomized
rats. The effects of ProvinolsTM alone were compared with those of
spironolactone alone in another series of uninephrectomized
control rats.
Figure 1. Circulating microparticles (MPs). Total MPs (A), platelet (CD61+)- (B), endothelial (CD54+)- (C) and erythrocyte- (D) derived MPs from
control, spironolactone (Spiro), ProvinolsTM (Prov), aldosterone-salt (Aldo-salt), Aldo-salt Spiro and Aldo-salt Prov (n = 4–5 for each group). Values are
means 6 SEM, *P,0.05 vs control rats. #P,0.05 ##P,0.01 vs Aldo-salt rats.
doi:10.1371/journal.pone.0039235.g001
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Methods
Animals
Male Sprague-Dawley (SD) rats (n = 149), uninephrectomized
at 7 weeks of age, were purchased when 8 weeks old from
Charles River (France). All rats were housed in individual cages
and were fed a standard rat chow and tap water ad libitum.
They were maintained in a quiet room at constant temperature
(20 to 22uC) and humidity (50 to 60%). The rats were
randomly divided into 6 groups. In the control group (n = 41),
the uninephrectomized SD rats received normal food for 4
weeks without aldosterone (Sigma-Aldrich, St Louis, MO)
administration. In the spironolactone (Sigma-Aldrich) group
(n = 12), rats received spironolactone (30 mg.kg21.day21) in the
food (based on an average consumption of 25 g.day21) for 4
weeks without aldosterone administration. In the ProvinolsTM
group (n = 12), rats received ProvinolsTM 20 mg.kg21.day21 in
their food [17] without aldosterone administration. In the
aldosterone-salt group (n = 28), osmotic mini-pumps were
implanted subcutaneously between the shoulder blades (Alzet
model 2004, 1 mg.h21) for continuous subcutaneous infusion for
4 weeks. Osmotic mini-pumps were filled with aldosterone and
incubated for several hours at 37uC prior to implantation.
Surgery was performed using an aseptic technique and the rats
were anaesthetized with isofluorane 1.5% in oxygen. The
aldosterone-salt group rats received 1% NaCl solution (plus
0.1% KCl) to drink, provided in a single drinking burette. In
the aldosterone-salt spironolactone group (n = 26), aldosterone-
salt rats received spironolactone (30 mg.kg21.day21) in the food
and in the aldosterone-salt ProvinolsTM group (n = 30), aldoste-
rone-salt rats received ProvinolsTM (20 mg.kg21.day21) in their
food. ProvinolsTM were obtained from the Socie´te´ Franc¸aise des
Distilleries Union de Coope´ratives Agricoles (Vallon Pont d’Arc,
France). The composition, in mg.g21 of dry powder, is: 480
proanthocyanidins, 61 total anthocyanins, 19 free anthocyanins,
38 catechin, 18 hydroxycinnamic acids, 14 flavonols and 370
polymeric tannins. All procedures were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals
published by the US National Institute of Health and were
approved by the local ethical committee ‘‘Comite´ regional
Nancy-Lorraine/Nord-Est’’ (nu B54-547-20).
Table 1. Effects of treatment by spironolactone (Spiro) or ProvinolsTM (Prov) on blood pressure, carotid diameter and organ
weights in aldosterone-salt (Aldo-salt) treated rats.
Group Control Aldo-salt Aldo-salt Spiro Aldo-salt Prov
N 17 14 10 16
Body weight (g) 40466 39466 43168*# 41766#
DAP (mmHg) 12465 13566 13463 14165
SAP (mmHg) 16766 19268* 18064 19868*
MAP (mmHg) 13865 15467 14963 16066
PP (mmHg) 4262 5763* 4661# 5763*
Diameter at MAP (mm) 1.2660.04 1.3260.05 1.2260.07 1.2560.05
Heart weight (g) 1.3160.05 1.6460.05* 1.5360.05*# 1.6060.05*
Kidney weight (g) 2.0260.04 2.4460.06* 2.4860.06* 2.6060.10*
DAP: diastolic arterial pressure; SAP: systolic arterial pressure; MAP: mean arterial blood pressure; PP: pulse pressure.
Values are means 6 SEM.
*P,0.05 vs Control.
#P,0.05 vs Aldo-salt.
doi:10.1371/journal.pone.0039235.t001
Figure 2. Carotid artery incremental elastic modulus-wall stress
(Einc-WS) curves. A. Einc-WS curves from Control, aldosterone-salt
(Aldo-salt), Aldo-salt spironolactone (Aldo-salt Spiro) and Aldo-salt
ProvinolsTM (Aldo-salt Prov) rats (n = 5 for each group). B. Mean value of
WS at 1500 kPa of Einc. Values are means 6 SEM, *P,0.05 vs control
rats.
doi:10.1371/journal.pone.0039235.g002
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Microparticle Isolation and Characterization
Blood obtained by intracardiac puncture was collected in
citrated tubes and processed for assay within 2 hours. Samples
were centrifuged 3 minutes at 1900 g and then 4 minutes at 5000 g
to obtain platelet-free plasma (PFP) and stored at 280uC until
subsequent use. Discrimination between the various membrane
microparticle subpopulations present in PFP was achieved by
analyzing the expression of membrane-specific antigens, as
previously described [18]. Quantification and phenotype of
endothelial, platelet, and erythrocyte microparticles were per-
formed using anti-CD54-biotin (1.5 mg.ml21), anti-CD61-FITC
(2.5 mg.ml21) (BioLegend, San Diego, CA) and anti-erythroid cell-
biotin (2.5 mg.ml21) (BD Biosciences, San Jose, CA) labeling. For
biotin-conjugated antibodies, streptavidin-FITC (2.5 mg.ml21)
(Sigma-Aldrich) was added for 15 minutes. Eight ml of plasma
were incubated with 5 ml of specific antibody (Beckman Coulter,
Villepinte, France). Irrelevant rat IgG was used as an isotype-
matched negative control for each sample. After 45 minutes of
incubation at room temperature, samples were diluted in 300 ml of
0.9% saline salt solution. Then 8 ml of Flowcount beads were
added and samples were analyzed in a flow cytometer 500 MPL
system (Beckman Coulter).
Von Willebrand Factor ELISA
Circulating von Willebrand factor (vWF) antigen was
measured by ELISA (AsserachromH, Diagnostica Stago, As-
nie`res, France). Each plasma sample was assayed at two
different dilutions chosen in order to interpolate results using
the calibration curve obtained with the human calibrator
supplied within the kit.
Carotid Artery Stiffness
We performed simultaneous recording of arterial diameter (left
carotid artery) and blood pressure (right carotid artery) in
pentobarbital-anesthetized rats as has been described previously
[2]. Arterial diameter measurement was obtained by using an
ultrasonic echo-tracking device (Diarad-00, Asulab SA). The
relationship between the pressure (P) and the lumen cross-sectional
area (LCSA) was fitted with the model of Tardy et al. [19] by using
an arctangent function and three optimal fit parameters (a, b, c) as
follows:
LCSA~a
p
2
z tan{1
P{b
c
  
ð1Þ
Carotid cross-sectional distensibility (Dist), a derivative of this
function, was used to assess the global elastic behaviour of the
artery. Circumferential wall stress (s) and Einc, which char-
acterises the intrinsic mechanical properties of the wall material,
were calculated with the above-mentioned parameters. Dist, s and
Einc are given by the following equations:
Dist Pð Þ~ 1
LCSA
|
dLCSA
dP
ð2Þ
s~
2LCSA|P
MCSA
ð3Þ
Einc~
3
Dist
1z
LCSA
MCSA
 
ð4Þ
where the media cross sectional area (MCSA) was determined by
histomorphometry. The reproducibility was 361% (inter-observer
coefficient of variation of carotid diameter).
Aortic Composition
Insoluble elastin, total collagen and cell protein contents were
measured on descending thoracic aortae without homogenization,
as described previously [20]. Briefly, aortic segments were opened
longitudinally, the media separated from the adventitia and the
medial length measured under a microscope. Media were then
defatted, dried and their dry weight recorded. Medial cell proteins
were extracted by 0.3% sodium dodecyl sulfate (SDS) and
subsequently assayed and insoluble elastin was purified by the
hot alkali method and quantified by weighing. Proteins in the
NaOH extract were then hydrolysed, and total medial collagen
was quantified by assaying hydroxyproline in the hydrolysate,
using a colorimetric assay.
Table 2. Effects of treatment by Spironolactone (Spiro) or ProvinolsTM (Prov) on aortic medial composition in aldosterone-salt
(Aldo-salt) treated rats.
Group Control Aldo-salt Aldo-salt-Spiro Aldo-salt-Prov
N 11 9 10 10
Dry weight (mg/cm) 2.6960.07 3.0360.15* 2.9060.08 2.9360.09
Cell proteins (% dry wt) 13.360.3 16.560.4* 14.460.6# 16.860.5*
Cell proteins (mg/cm) 0.3460.01 0.4860.03* 0.4060.02*# 0.4760.01*
N 5 4 4 6
Elastin (% dry wt) 52.760.3 43.261.2* 48.561.0*# 46.660.8*#
Elastin (mg/cm) 1.3960.06 1.3260.07 1.4260.04 1.2460.05
Collagen (% dry wt) 13.660.2 12.860.2 12.960.7 13.060.3
Collagen (mg/cm) 0.3660.02 0.3960.030 0.3860.03 0.3560.02
Elastin/collagen 3.8960.07 3.3760.09* 3.8060.20 3.6060.10
Values are means 6 SEM P,0.05 vs Control, #P,0.05 vs Aldo-salt.
doi:10.1371/journal.pone.0039235.t002
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NO Spin Trapping and Electronic Paramagnetic
Resonance Technique (EPR) Studies
The detection of NO production was performed using the
technique with Fe2+ diethyldithio-carbamate (DETC, Sigma-
Aldrich) as spin trap [21]. To measure NO production in blood,
we injected 400 mg.kg21 of DETC (1 ml.g21 weight) intraperito-
neally and 40 mg.kg21 of FeSO4.7H2O (1 ml.g
21 weight), in a
solution containing sodium citrate dehydrate 200 mg.ml21,
subcutaneously. After 30 minutes, rats were anesthetized with
isoflurane and killed, and venous blood was obtained for NO
measurements. These studies were performed on a table-top x-
band spectrometer Miniscope (Magnettech, Berlin, Germany).
Recordings were made at 77uK, using a Dewar flask. Instrument
settings were 10 mW of microwave power, 1 mT of amplitude
modulation, 100 kHz of modulation frequency, 60 seconds of
sweep time and 3 scans. Blood samples exhibited an EPR
characteristic of signals derived from NO-Fe(DETC)2 [22]. The
quantitative measurement of the NO-Fe(DETC)2 signal amplitude
was expressed in relative units.ml21 of blood (amplitude per ml).
In another set of experiments, animals were killed and aorta
dissected and incubated for NO production in 250 ml of Krebs–
Hepes buffer solution, then treated with 250 ml of Fe(DETC)2 and
incubated for 45 minutes at 37uC. NO detection was measured in
situ by EPR as described above, and values were corrected for the
dry weight of the sample (dehydrated sample) in mg and expressed
as amplitude signal per mg (Wds).
Superoxide Anion (O2
2) Determination by EPR
Aorta was dissected and allowed to equilibrate in deferoxamin-
chelated Krebs-Hepes solution containing 1-hydroxy-3-methox-
ycarbonyl-2,2,5,5-tetramethylpyrrolidin (CMH; Noxygen, Mainz,
Germany) (500 mM), deferoxamine (25 mM) and DETC (5 mM) at
37uC for 20 minutes. O2
2 detection was measured in situ by EPR,
and values are expressed as amplitude of signal per mg dehydrated
tissue (dry weight).
Western Blotting
Seventy-five mg of total proteins from aortae and 20 mg of total
proteins from VSMCs were loaded onto 8% or 10% SDS-PAGE.
Proteins were transferred to nitrocellulose membranes and
incubated overnight (4uC) with a monoclonal mouse anti-iNOS
(1:500, BD Transduction Laboratories), a mouse anti-IkBalpha
phosphorylated (Ser32/36) (1:1000, USBiological, Swampscott,
MA), a rabbit polyclonal NFkB p65 antibody (1:400, Abcam,
Cambridge, UK), anti-caspase-8 and anti-caspase-3 (1:1000, Cell
Signaling Technology, Danvers, MA) or a mouse tubulin antibody
(1:200, Sigma-Aldrich). Bound antibodies were detected with a
secondary peroxidase-conjugated anti-mouse or anti-rabbit IgG
(1:500, Pierce, Perbio Science France, Brebie`res, France). The
bands were visualized using the enhanced chemiluminescence
system (Super Signal West Femto Maximum Sensitivity Substrate,
Pierce), quantified by densitometry and normalized to tubulin or
b-actin expression. Results were expressed as the percentage of
staining compared with control aortae or VSMCs taken as 100%.
Aortic Nitrotyrosine Staining
Fixed sections from the aortae were incubated in blocking buffer
(5% non-fat dry milk) for nitrotyrosine. Then, tissue sections were
incubated overnight (4uC) with a mouse monoclonal anti-
nitrotyrosine (clone 1A6) antibody (1:100, Millipore, Billerica,
MA, ref: 05-233) in blocking buffer. Three washes were followed
by incubation with secondary murine fluorescence-labeled anti-
body Alexa fluor-488 (1:100, Molecular Probes, Cergy Pontoise,
France). Controls were performed by omission of the first or
second antibody. After washing, vessel sections were mounted on
glass slides. Confocal equipment mounted on a Nikon Eclipse, TE
200-S, inverted microscope was used for optical sectioning of the
tissue. Digital image recording was performed using the QED In
Vivo Software.
Vascular Reactivity
Second generation branches of small mesenteric arteries (SMA)
werecarefullyremovedandarterial segmentsweremountedonawire
myograph filled with physiological salt solution (PSS) of the following
composition in mM: NaCl 130, NaHCO3 14.9, KCl 3.7, KH2PO4
1.2, MgSO4.7H2O 1.2, CaCl2.H2O 1.6 and glucose 11, under
normalized tension, as previously described [10]. Briefly, SMA were
stretched to 200 mg, lengths that yielded circumferences equivalent
to 90% of those which the vessels would have had with an intramural
pressure of 100 mmHg (i.e., the pressure corresponds to the
physiological value). PSS was kept at 37uC and gassed with 95% O2
and 5% CO2 at pH 7.4. Mechanical activity was recorded
isometrically by a force transducer (Danish Myo Technology,
Aarhus, Denmark). After setting the vessels to their working length,
the contractile response to KCl (80 mM) was assessed. After washing
of arteries, challenges with phenylephrine (Sigma Aldrich) were
performed to elicit a contractile response and to test their maximal
contractile capacity. Arteries were pre-contracted at 80% of their
maximal contraction with phenylephrine. When the contraction
reached a plateau, cumulative application of acetylcholine (1 nM to
10 mM, Sigma Aldrich) was performed. The presence of functional
endothelium was assessed by the ability to induce more than 50%
relaxation of vessels pre-contracted with phenylephrine. Parameters
of vascular sensitivity were analyzed by means of pD2 = -log EC50,
EC50 being the molar concentrationof the agonist that produces50%
of the maximal effect; EC50 values were calculated by logit-log
regression.
Flow-mediated dilatation. Isolated SMAs (,130–160 mm
of diameter) were cannulated at both ends in a video-monitored
perfusion system (Living Systems Instrumentation, Burlington,
VT). Arteries were bathed in physiological salt solution at pH 7.4,
PO2 160 mmHg, PCO2 37 mmHg, as described previously [23].
The presence of endothelium was tested by applying acetylcholine
after pre-contraction of the arteries with KCl-depolarization
(80 mM). Diameter changes were measured when intra-luminal
pressure was increased from 10 to 125 mmHg. Pressure was then
set at 75 mmHg and dilatation in response to flow was evaluated.
Dilatation response-to-flow experiments were repeated in series in
presence of the NOS inhibitor, N$ nitro-L-arginine (L-NA,
100 mM, Sigma-Aldrich). The NO-dependent dilatation was
calculated as the difference between the dilatation without
inhibitor and that in the presence of L-NA.
Figure 3. NO production, iNOS and NFkB pathways. Quantification of the amplitude of NO-Fe(DETC)2 signal per ml in blood (A) and per mg of
dried sample in aorta (B). Values are means 6 SEM, *P,0.05 vs control rats, #P,0.05 vs Aldo-salt rats (n = 4–5 for each group). Western blot (C) and
densitometric analysis revealing iNOS (D), NFkB p65 (E) expression and phosphorylated I-kB alpha (P-IkB; F) in aortae. Values are means 6 SEM,
*P,0.05 vs control rats, #P,0.05 vs Aldo-salt rats.
doi:10.1371/journal.pone.0039235.g003
Aldosterone, Microparticles and Endothelium
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e39235
Shear Stress-induced Microparticle Formation
Shear-induced blood cell activation was evaluated in vitro using
an erythroaggregometer (Couette flow, SD Medical), subjecting
citrated anticoagulated whole blood (from Sprague Dawley rats via
a carotid catheter under isoflourane anaesthesia) (129 mM; v/v
9:1) to shear rates of 300 s21 for 2 minutes at 37uC. Samples were
incubated with aldosterone at 10 nM for 10 min. The following
antagonists were added 10 min prior to the addition of aldoste-
rone: the mineralcorticoid receptor antagonist, spironolactone, at
1 mM, ProvinolsTM at 0.01 g.l21 or the oestrogen receptor
antagonist, fulvestrant (Fulv; Sigma-Aldrich), at 1 mM. Controls
were performed in which citrated whole blood was in contact with
the cup and bob for 2 minutes at 37uC but not exposed to shear
stress. Samples were then centrifuged for 10 minutes at 190 g to
obtain platelet-rich plasma (PRP) and then for 3 minutes at
1900 g. The supernatant was centrifuged for 4 min at 5000 g to
obtain the platelet-poor plasma (PPP). Platelet activation and the
generation of cell-derived microparticles in sheared blood samples
were evaluated using the chromogenic assay measuring the
phospholipid-related procoagulant activity (PPA) as previously
described [24].
Vascular Smooth Muscle Cell Isolation and Culture
Primary rat aortic vascular smooth muscle cells (VSMCs) were
isolated by using standard enzymatic dissociation techniques, as
previously reported [25]. Cells were plated and grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 5% fetal bovine serum, and cultured at 37˚C in air containing
5% CO2. Cells were used at passage 2. Before treatment, cells
were serum-starved for 12 hours.
MDM2, cardiotrophin-1 (CT-1) and gp91 are genes induced by
aldosterone in a mineralocorticoid-dependent pathway [25–27].
VSMCs were incubated with aldosterone at 10 nM for 24 hours.
The following antagonists were added one hour prior to the
addition of aldosterone: the mineral corticoid receptor antagonist,
spironolactone, at 1 mM, ProvinolsTM at 0.01 g.L21, or the
oestrogen receptor antagonist, fulvestrant, at 1 mM.
Statistical Analysis
All values are expressed as means 6 SEM. One-way analysis of
variance was performed to compare the different groups of rats.
The Fisher test was used for inter-group comparisons. Einc was log
transformed to generate linear relationships [28]. After this
transformation, we calculated the mean slopes of the curves. If
Figure 4. Superoxide anion and nitrotyrosine staining in aorta. Quantification of the amplitude of O2
–CMH signal (A) and
immunohistochemical staining for nitrotyrosine (B-E) in aortae (n = 4–5 for each group). Values are means 6 SEM, *P,0.05 vs control rats,
#P,0.05 vs Aldo-salt rats.
doi:10.1371/journal.pone.0039235.g004
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the slopes were not significantly different, we compared the curves
within the common range of Einc for WS by calculating WS at
1500 kPa of Einc. Differences were considered significant at values
of P,0.05. Statistical analyses of PD2 values and maximal effects
of acetylcholine were performed by two-way analysis of variance,
and nonparametric Mann-Whitney U tests or analysis of variance
for repeated measures and subsequent Bonferroni post hoc test.
Results
Arterial Pressure and Organ Weights
Aldosterone-salt treatment increased significantly SAP and
pulse pressure (PP) compared to controls. There were no
significant changes observed in body weight, diastolic or mean
blood pressures or in carotid artery diameter. The significant
increase in SAP and PP due to aldosterone-salt treatment was
prevented by spironolactone treatment but not by ProvinolsTM
(Table 1). When administered alone, spironolactone but not
ProvinolsTM exerted an inhibitory effect on blood pressure (Table
S1). Spironolactone and ProvinolsTM treatment increased body
weight compared to the aldosterone-salt group (Table 1). The
increases in heart and kidney weights induced by the aldosterone-
salt treatment were not influenced by ProvinolsTM whereas
spironolactone partially prevented the increase in heart weight.
Microparticle Counts and their Cellular Origin
Aldosterone-salt treatment increased significantly the total
number of circulating microparticles when compared to control
(Figure 1A). This increase in the total number of microparticles
was completely prevented by both spironolactone and Provi-
nolsTM. Neither spironolactone nor ProvinolsTM alone had any
effect on the total number of microparticles (Figure 1A). Pheno-
typical characterization of the cellular origin of microparticles
showed significant increases in platelet-, endothelial- and erythro-
cyte-derived microparticles in aldosterone-salt-treated rats
(Figures 1B–D) which were all inhibited by both spironolactone
and ProvinolsTM. In addition, both spironolactone and Provi-
nolsTM alone significantly reduced platelet- and endothelial-
derived microparticles, without modifying erythrocyte-derived
microparticle number (Figure 1B–D).
Von Willebrand Factor
There was an increase in circulating vWF in aldosterone-salt
rats (3.460.4 versus 2.260.3 mg.ml21 in controls; n = 7 and 11
respectively; p = 0.02) which was inhibited by both spironolactone
(2.260.3 mg.ml21; n = 9) and ProvinolsTM (2.160.3 mg.ml21;
n = 10).
Incremental Elastic Modulus-wall Stress Curves
Figure 2A shows Einc-WS curves in four groups of rats. To
compare these curves, we calculated the mean WS at 1500 kPa of
Einc (Figure 2B). Comparison of Einc-WS curves from aldoste-
rone-salt and control rats showed a significant reduction in WS at
1500 kPa of Einc in aldosterone-salt rats indicating increased
arterial stiffness. In the spironolactone group, this increase was not
observed. However, ProvinolsTM did not significantly prevent
aldosterone-salt-induced arterial stiffness. The Einc-WS curves
from rats treated with spironolactone or ProvinolsTM alone were
not different from the control group (Figure S1).
Aortic Composition
Thoracic aortic medial dry weight per cm length, and cell
protein content were increased significantly by the aldosterone-
salt treatment compared with control rats (Table 2), indicating
Figure 5. Endothelial function in small mesenteric arteries. A:
Flow-induced dilatation in small mesenteric arteries from control,
aldosterone-salt (Aldo-salt), aldosterone-salt spironolactone (Aldo-salt
Spiro) and aldosterone-salt ProvinolsTM (Aldo-salt Prov) calculated as
Ddiameter. Absolute values for baseline diameters were 13369, 13667,
14265 and 15366 mm, respectively. *P,0.05 Aldo-salt vs control. B:
NO-dependent dilatation calculated as the difference between the
dilatation in basal conditions and the dilatation in the presence of N$
nitro-L-arginine (L-NA, 100 mM). Absolute values for baseline diameters
ere 13364, 13564, 14366 and 15464 mm, respectively. n = 5 for each
group. Values are means 6 SEM. *P,0.05 Aldo-salt vs control vessels.
doi:10.1371/journal.pone.0039235.g005
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that hypertrophy of the media had occurred. The increased dry
weight reflects not only the increase in smooth muscle cell
content but also an increase in some extracellular components
not quantified here (principally proteoglycans and glycoproteins)
and deduced by substraction. The significant increase in aortic
dry weight due to aldosterone-salt was not observed under co-
Figure 6. Shear stress and microparticle formation. (A) Phospholipid-related procoagulant activity (PPA) values are expressed as a ratio
between sheared and unsheared data from blood samples treated with aldosterone (Aldo), aldosterone plus spironolactone (Aldo+Spiro) and
aldosterone plus ProvinolsTM (Aldo+Prov) groups (n = 4–5 for each group). Values are means 6 SEM, *P,0.05 vs control (PBS). #P,0.05 vs
aldosterone-treated samples. (B-E). Mineralocorticoid receptor antagonist activity. VSMCs were preincubated with spironolactone (Spiro), ProvinolsTM
(Prov) or fulvestrant (Fluv) for 1 hour, and then aldosterone (Aldo) was added for 24 hours for protein analysis. Changes in MDM2 (C), gp91 (D) and
CT-1 (E) protein expression were assayed by Western Blotting and normalized with b-actin in triplicate. A representative Western blot (B) and the
histograms with bars represent the means 6 SEM of triplicates in three independent experiments. *P,0.01 vs Control.
doi:10.1371/journal.pone.0039235.g006
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treatment with spironolactone or ProvinolsTM. However, only
spironolactone, but not ProvinolsTM, was able to significantly
attenuate the aldosterone-salt-induced increase in cell proteins.
A significant decrease in the percentage of elastin in the thoracic
aorta with aldosterone-salt treatment was observed, which was
only partially corrected by both spironolactone and ProvinolsTM
treatments. There were no changes in collagen with aldosterone-
salt treatment. However, as the proportion of elastin was
decreased, there was a significant reduction in the elastin to
collagen ratio after aldosterone-salt treatment. Both spironolac-
tone and ProvinolsTM partially prevented this reduction in elastin/
collagen providing values approaching those of controls.
NO production, iNOS, NFkB p65 and phosphorylated-IkB
alpha activation
The NO-Fe(DETC)2 EPR signal was greater in blood and aorta
from aldosterone-salt treated rats than in control rats (Figures 3A
and 3B, respectively). This increase was completely prevented by
spironolactone or ProvinolsTM. Neither spironolactone nor
ProvinolsTM alone had any effect on aortic NO production
(Figure S2).
Western blot analysis showed an increase in iNOS expression in
aortae from aldosterone-salt rats compared to those from control
rats (Figures 3C and 3D). Much less staining was observed
following treatment with spironolactone or ProvinolsTM. The
iNOS expression was associated with an increase in NFkB p65
expression in aortae from aldosterone-salt rats compared to
control rats (Figures 3C and 3E). Activation of the transcriptional
factor, NFkB p65, in aortae from aldosterone-salt treated rats was
confirmed by the increased levels of phosphorylated-IkB alpha
compared to control vessels (Figures 3C and 3F). All these effects
of aldosterone-salt treatment on iNOS and NFkB p65 expression
and phosphorylated-IkB alpha were completely prevented both by
spironolactone and by ProvinolsTM.
Oxidative and Nitrosative Stresses
EPR measurement of oxidative stress demonstrated that aortae
from aldosterone-salt-treated rats displayed an increased O2
-
production compared with controls that was prevented by both
spironolactone and ProvinolsTM (Figure 4A). Neither spironolac-
tone alone nor ProvinolsTM alone affected O2
- production
(Figure 4).
Aortae from aldosterone-salt rats also showed a marked increase
in nitrotyrosine staining, reflecting an increased degree of protein
nitration in the vascular wall (Figures 4B and C). Weak staining,
comparable to that obtained in control aorta, was found in vessels
from aldosterone-salt rats treated either with spironolactone or
ProvinolsTM (Figures 4D and E).
Vascular Reactivity in Small Mesenteric Arteries
The contractile response to KCl-depolarization (80 mM) did
not differ between control rats and the other groups. However,
contraction to KCl was increased in aldosterone-salt rats when
compared with the treatment spironolactone alone. Endothelium-
dependent relaxation in response to acetylcholine was not
significantly different in vessels harvested from the different groups
of rats (Table 3).
Figure 7. Effects on vessel wall apoptosis. Western blot and densitometric analysis revealing expression of cleaved caspase-8 and caspase-3 in
aortae. Data are representative of at least four independent experiments. Values are means6 SEM, *P,0.05 vs control rats, #P,0.05 vs Aldo-salt rats.
doi:10.1371/journal.pone.0039235.g007
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Flow increases induced a significant vasodilator response in
all the 4 groups of rats studied (Figure 5A). This flow-induced
dilatation was significantly reduced in small mesenteric arteries
from the aldosterone-salt-treated rats compared to those from
control. Treatment by spironolactone and ProvinolsTM normal-
ized the effect of aldosterone-salt on flow-induced dilatation.
Moreover, the NO-dependent dilatation (Figure 5B) was
calculated as the difference between the dilatation without L-NA,
represented in Figure 5A, and the dilatation in presence of L-NA
(not shown). The NO-component of flow-induced dilatation was
reduced in arteries from aldosterone-salt-treated rats compared to
vessels from control rats. Treatment either with spironolactone or
ProvinolsTM largely corrected this aldosterone-salt-induced effect.
Shear Stress and Microparticle Formation
Figure 6A shows the PPA ratio values in PPP obtained from
sheared and unsheared samples of total rat blood. Shear stress
induced an increase in microparticle production in control
samples. Treatment with aldosterone potentiated this shear-
induced production. This effect was completely inhibited by
spironolactone but not by ProvinolsTM. This absence of
mineralocorticoid receptor antagonist activity of ProvinolsTM
was further supported by the inability of ProvinolsTM to block
the aldosterone-induced increase in the expression of MDM2,
gp91 and cardiotrophin-1 (CT-1) by cultured primary rat
vascular smooth muscle cells (Figure 6 B–E). Estrogen receptor
blockade with fulvestrant inhibited the effect of shear stress.
However, in the absence of shear stress, aldosterone did not
induce microparticle production by cultured human aortic
endothelial cells (12266 versus 13064 nM equivalent phospha-
tidylserine in control cells).
Spironolactone and Provinols Prevent Aldosterone-
induced Apoptosis in the Vessel Wall
As shown in Figure 7, vessels from aldosterone-salt group
display expression of cleaved caspase-8 and caspase-3, indicating
that aldosterone-salt treatment induces apoptosis of vessel wall. In
addition, both Spirolactone and Provinols prevented aldosterone-
salt-induced apoptosis as reflected by the reduction of caspase
cleavage.
Discussion
We report that aldosterone-salt-induced hypertension produced
a marked increase in both circulating microparticles, especially
those from platelets, endothelium and erythrocytes, and circulating
vWF. The microparticle increase was accompanied by increases in
aortic stiffness, oxidative and nitrosative stresses and microvascular
endothelial dysfunction as well as induction of apoptosis in the
vessel wall. Of particular interest is that ProvinolsTM prevented
changes in circulating microparticles, microvascular endothelial
dysfunction, oxidative and nitrosative stress and apoptosis. The
effects of these polyphenols were not mediated by mineralocor-
ticoid receptors or changes in shear stress. However, ProvinolsTM
did not block the aldosterone-salt-induced increases in aortic
hypertrophy, stiffness or SAP.
Microparticle levels reflect the severity of endothelial alterations
and of platelet activation. Although the precise mechanisms of
microparticle production remain unclear, it has been emphasized
that shear stress contributes to microparticle release whatever their
cellular origin, as we have demonstrated in our in vitro studies. An
effect of hypertension on microparticle production is supported by
the correlation between plasma levels of endothelial and platelet
microparticles and blood pressure in patients with severe untreated
hypertension [29]. Besides reflecting the state of the parent cells,
there is growing consensus on the many facets of microparticles
which can act as diffusible messengers with either beneficial or
deleterious missions [6,30]. In particular, a functional or causative
role of microparticles on endothelial dysfunction has been reported
in several studies involving in vitro incubation of microparticles with
endothelial cells or rings from thoracic aortae or their injection
into mice [8,31–36]. Although a possible direct effect of
microparticles was not assessed on different types of arteries, they
might contribute to the blood vessel inflammation observed in the
present study (see below). For example, microparticles harvested
from patients with pre-eclampsia induce activation of the
transcription factor RelA/NFkB associated with an up-regulation
of proinflammatory protein expression, namely iNOS and COX-
2, in the vessel wall. The proinflammatory properties of these
microparticles lead to the observation of surrogate signs of
oxidative and nitrosative stress in the vascular wall [26]. The
same type of inflammation was seen in the aorta from aldosterone-
salt-treated rats. Finally, spironolactone or ProvinolsTM alone
decreased endothelial-derived microparticle levels. Spironolactone
[37] as well as red wine polyphenols [38] protect endothelial cells
against apoptosis, a cellular process releasing microparticles.
Similar mechanisms may explain the effects of spironolactone
and ProvinolsTM on endothelial-derived microparticle release.
This hypothesis is reinforced by the fact that spironolactone or
Table 3. Contractile effects of KCl (80 mM) and endothelium-dependent relaxation to acetylcholine in rat mesenteric resistance
arteries.
KCl-induced contraction mN/mm Endothelium-dependent relaxation to acetylcholine
pD2 Maximal effect (% relaxation)
Control 4.4560.44 7.5060.15 92.965.1
Spiro 3.7660.17 7.0660.13 92.262.4
Prov 3.7160.68 7.1360.22 87.165.8
Aldo-salt 4.9160.46 7.3760.06 98.361.3
Aldo-salt Spiro 3.9260.48 7.4160.17 97.861.2
Aldo-salt Prov 4.0260.29 7.2460.21 97.261.6
Spironolactone = Spiro; ProvinolsTM = Prov; Aldosterone-salt = Aldo-salt.
Values are means 6 SEM (n = 4–6).
*P,0.05 vs Spiro.
doi:10.1371/journal.pone.0039235.t003
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ProvinolsTM prevented apoptosis induced by aldosterone-salt
treatment at the level of the vessel wall.
Blockade of the aldosterone pathway by spironolactone or
treatment by ProvinolsTM prevented the increase in circulating
microparticles and plasma vWF as well as the associated vascular
inflammation. Recently, aldosterone has been reported to activate
endothelial vWF exocytosis at the cellular level [39]. Although
microparticle generation and vWF release represent distinctive
phenomena they may both be involved in aldosterone-salt-induced
vascular inflammation. Even though it has been shown that
selective mineralocorticoid receptor inhibition decreases platelet
activation, the mechanism responsible for these effects has not
been defined [40]. Lijnen and Petrov [41] described that
spironolactone decreased intraerythrocyte and intraplatelet Na+
and Ca2+ by decreasing Na+-pump activity. It is possible that the
reduction in platelet microparticle levels observed in the present
study is associated with a lower increase in intracellular Ca2+ in
platelets because microparticle release is a Ca2+-dependent process
[6]. Polyphenols lead to inhibition of whole-blood aggregation
suggesting a potential mechanism for the beneficial effects of
polyphenols by the suppression of platelet-mediated thrombosis
[42].
A significant correlation between endothelial microparticles
and the loss of flow-mediated dilatation has been previously
reported in obstructive sleep apnea [43] and in patients with
end-stage renal failure [44] supporting the idea that these
measurements are reliable indices of endothelial dysfunction.
Thus, reduction of circulating microparticles may protect
against endothelial dysfunction as evidenced by normalization
of flow-mediated dilatation and intense vascular wall inflamma-
tion in our experimental model of hypertension. It is noteworthy
that ProvinolsTM did not prevent the in vitro aldosterone-induced
increase in microparticle production via shear stress. Although
the in vitro conditions may not completely mimic the in vivo
situation regarding extracellular Ca2+ and the level of shear
stress, this result suggests that the in vivo effect of ProvinolsTM
on microparticle levels was not dependent on shear stress.
The systolic hypertension observed in this model may be the
result of the increase in stiffness of the vascular wall, as previously
shown [2]. The significant increase in aortic dry weight and in cell
proteins in aldosterone-salt rats reflects arterial wall hypertrophy,
in accordance with previous studies [2,45]. The finding of an
increase in cell protein content but not of collagen is consistent
with previous data showing an absence of collagen accumulation
within the media in rats receiving aldosterone for 6 weeks [46].
The decreased elastin/collagen ratio and the increased cell protein
content observed could partly explain the increased arterial
stiffness, which is independent of any change in collagen.
In our study, in contrast to spironolactone, treatment with
ProvinolsTM was not able to correct the hypertension. Previous
studies have, however, reported antihypertensive effects of red
wine polyphenol compounds, including ProvinolsTM, in a rat
DOCA-salt model of hypertension [47] and in other rat models;
salt-sensitive, angiotensin II administration, NO-inhibition or the
spontaneously hypertensive rat. However, in none of these models
were the effects of ProvinolsTM compared to that of a mineral-
ocorticoid receptor antagonist. In our model, systolic hypertension
is dependent on the action of aldosterone on the mineralocorticoid
receptor as demonstrated by the preventive effect of spironolac-
tone. The hypotensive effect in control rats was also consistent
with the permanent vascular tone driven by the microparticles.
The absence of effect of ProvinolsTM on systolic hypertension
could support the hypothesis that the effect in other models is
related to interference with the renin angiotensin system, the NO
pathway or the sympathetic nervous system [11,12]. In agreement
with this hypothesis, Provinols has no effect in control rats without
changes in these pathways. Furthermore, spironolactone has been
shown not to significantly lower systolic blood pressure in Ang II-
infused rat [48]. This suggests that the effects of ProvinolsTM are
not mediated via the mineralocorticoid receptor.
Aldosterone-salt-treated rats exhibited increased circulating and
aortic NO levels. These effects were associated with an upregula-
tion of iNOS in the vascular wall which was prevented by
spironolactone and ProvinolsTM. In line with this, we have
reported in L-NAME hypertensive rats that the increase of iNOS
expression in the aorta is reduced in rats treated with ProvinolsTM
[12]. Moreover, we provide evidence that the effect of aldosterone
is also associated with an increased oxidative stress, marked by
increased aortic O2
2 production, probably via activation of the
NADPH oxidase pathway [49]. An increase in O2
2 production
leads to an enhancement of its interaction with NO and to the
formation of the highly toxic ONOO2, as illustrated by the
protein nitration in the aorta. Peroxynitrite is produced in large
amounts here and has harmful effects in various tissues, especially
in blood vessels. We demonstrate that spironolactone prevents the
increase in O2
2 production in the aorta as well as attenuating
aldosterone-salt-induced ONOO2 production. ProvinolsTM pre-
vented the increase in aortic O2
2 production, probably due to
their capacity to reduce aortic p22phox gene overexpression,
observed in accordance with the work of Jimenez et al. [47] in
DOCA-salt animals. This effect leads to reduced formation of
ONOO2 and is also concomitant with a decrease in NFkB which
is upstream to iNOS induction. Taken together, these data
highlight both the anti-inflammatory effect and the decrease in
oxidative stress induced by ProvinolsTM in the aorta, and therefore
extend this beneficial action of polyphenols to aldosterone-salt-
induced hypertension.
As for endothelial function, studies have shown that chronic
treatment with aldosterone results in impaired acetylcholine-
induced relaxation of the aorta in both normotensive and
hypertensive rats via the production of cyclo-oxygenase 2
metabolites [5]. In small mesenteric arteries, we found that the
response to acetylcholine was not altered whereas the vasodilator
response to flow was reduced. This endothelial dysfunction in
aldosterone-salt-treated rats was associated with a decrease in the
NO component of shear stress. The mechanism by which
aldosterone impairs flow-induced NO vasodilatation may result
from the increase in oxidative stress that reduces endothelial NO
bioavailability. This finding is in agreement with a previous report
suggesting that increased NADPH-derived peroxide may be one
possible mechanism for the reduced NO component of flow-
mediated vasodilatation in SHR [50]. ProvinolsTM prevented
endothelial dysfunction at the level of the microcirculation which is
associated with enhanced endothelium-dependent relaxation
resulting from augmented NO generation via increased eNOS
activity and expression [9,11,12]. Also, we have reported that red
wine polyphenols evoke endothelium-dependent relaxation asso-
ciated with ERa-stimulation, c-Src/ERK1/2-mediated activation
of eNOS, with consequent endothelial NO release [14]. Such a
mechanism contributes probably to the beneficial effect of red
wine polyphenols.
In conclusion, this study demonstrates that aldosterone-salt
administration in rats is able to induce an increase in micropar-
ticles which is associated with endothelial dysfunction and vascular
inflammation, and leads to the appearance of various oxidative
stress markers. These arterial modifications could represent an
early step in the development of hypertension. These changes were
all reversed by spironolactone in all vascular territories, whereas
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the action of ProvinolsTM, which is independent of mineralocor-
ticoid receptor activity, preferentially affected the microcirculation
and the NO pathway. The impact of red wine polyphenols on the
production of microparticles and flow-induced dilatation provides
new insights for future development of therapeutic strategies in
aldosterone-mediated hypertension.
Supporting Information
Figure S1 Carotid artery incremental elastic modulus-
wall stress (Einc- WS) curves. A. Einc-WS curves from
Control, Spironolactone (Spiro) and ProvinolsTM (Prov) rats
(n = 5–9 for each group). B. Mean value of WS at 1500 kPa of
Einc. Values are means 6 SEM.
(TIF)
Figure S2 NO production in aorta. Quantification of the
amplitude of NO-Fe(DETC)2 signal (amplitude per mg of dried
sample Wds) in aorta from Control, Spironolactone (Spiro) and
ProvinolsTM (Prov) rats (n = 6 for each group).
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Table S1 Effects of treatment by spironolactone (Spiro)
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diameter and organ weights in rats.
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